Loading...
Loading...
LXRX| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.3M |
| Operating Expense | 44.5M |
| Operating I/L | -44.2M |
| Other Income/Expense | -0.7M |
| Interest Income | 1.3M |
| Pretax | -44.9M |
| Income Tax Expense | 1.2M |
| Net Income/Loss | -44.9M |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of orally-delivered small molecule drug candidates. Its lead products include Sotagliflozin, which has completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, and LX9211, currently in Phase II clinical development for neuropathic pain treatment. The company generates revenue through strategic collaboration and license agreements with industry leaders such as Bristol-Myers Squibb Company and Genentech, Inc., leveraging its innovative drug pipeline to address unmet medical needs and drive commercial success.
